Atorvastatin
| Subclass of | 7-{4-[anilino(oxo)methyl]-2-(4-fluorophenyl)-3-phenyl-5-propan-2-yl-1-pyrrolyl}-3,5-dihydroxyheptanoic acid  |
|---|---|
| Get use | Medication |
| Stereoisomer of | (3S,5R)-atorvastatin |
| Chemical formula | C₃₃H₃₅FN₂O₅ |
| Canonical SMILES | CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4 |
| Isomeric SMILES | CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4 |
| Active ingredient in | Lipitor |
| World Health Organisation international non-proprietary name | atorvastatin |
| Physically dey interact plus | 3-hydroxy-3-methylglutaryl-CoA reductase |
| Legal status (medicine) | medical prescription |
| Pregnancy category | Australian pregnancy category D, US pregnancy category X |
| LiverTox likelihood score | LiverTox toxicity likelihood category A |
| Subject has role | statin, anticholesteremic agents |
Atorvastatin, dem sell under de brand name Lipitor among odas, be a statin medication dem use to prevent cardiovascular disease insyd those at high risk den to treat abnormal lipid levels.[1] For de prevention of cardiovascular disease, statins be a first-line treatment insyd reducing cholesterol.[1] Dem dey take am by mouth.[1]
Common side effects fi include diarrhea, heartburn, nausea, muscle pain (typically mild den dose-dependent) den, less frequently, joint pain. Muscle symptoms often dey occur during de first year den be commonly influenced by pre-existing health issues den de nocebo effect.[2][3] Chaw patients fi continue therapy plus dose adjustment anaa statin switching. Rare (<0.1%) buh serious side effects fi include rhabdomyolysis (severe muscle disorder), liver problems den diabetes.[4] Ein use during pregnancy fi harm de fetus.[1] Like all statins, atorvastatin dey work by inhibiting HMG-CoA reductase, an enzyme dem find insyd de liver wey dey play a role in producing cholesterol.[1]
Na dem patent atorvastatin insyd 1986, wey na dem approve am for medical use insyd de United States insyd 1996.[1][5] E be on de World Health Organization's List of Essential Medicines.[6] E be available as a generic medication.[1][7] Insyd 2023, na e be de most commonly prescribed medication insyd de United States, plus more dan 115 million prescriptions filled for over 29 million people.[8][9] Insyd Australia, na e be one of de top ten most prescribed medications between 2017 den 2023.[10]
References
[edit | edit source]- 1 2 3 4 5 6 7 "Atorvastatin Calcium Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 25 October 2010. Retrieved 23 December 2018.
- ↑ Reith C, Baigent C, Blackwell L, Emberson J, Spata E, Davies K, Halls H, Holland L, Wilson K, Armitage J, Harper C, Preiss D, Roddick A, Keech A, Simes J, Collins R, Barnes E, Fulcher J, Herrington WG, Kirby A, Mihaylova B, O'Connell R, Amarenco P, Barter P, Betteridge DJ, Blazing M, Bosch J, Bowman L, Braunwald E, Cannon CP (September 2022). "Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials". Lancet. 400 (10355): 832–845. doi:10.1016/s0140-6736(22)01545-8. PMC 7613583. PMID 36049498.
- ↑ Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P, et al. (ASCOT Investigators) (June 2017). "Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase". Lancet. 389 (10088): 2473–2481. doi:10.1016/S0140-6736(17)31075-9. hdl:10044/1/50011. PMID 28476288.
- ↑ "Australian Medicines Handbook". amhonline.amh.net.au. Retrieved 11 May 2025.
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 473. ISBN 978-3-527-60749-5. Archived from the original on 12 January 2023. Retrieved 10 May 2020.
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ Hitchings A, Lonsdale D, Burrage D, Baker E (2014). The Top 100 Drugs e-book: Clinical Pharmacology and Practical Prescribing. Elsevier Health Sciences. p. 197. ISBN 978-0-7020-5515-7. Archived from the original on 26 February 2023. Retrieved 27 June 2022.
- ↑ "The Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ↑ "Atorvastatin Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 12 August 2025.
- ↑ "Medicines in the health system". Australian Institute of Health and Welfare. 2 July 2024. Retrieved 30 September 2024.
External links
[edit | edit source]
- Maggon K (June 2005). "Best-selling human medicines 2002–2004". Drug Discovery Today. 10 (11): 739–42. doi:10.1016/S1359-6446(05)03468-9. PMID 15922927.
- Simons J (20 January 2003). "The $10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering medication, has become the bestselling pharmaceutical in history. Here's how Pfizer did it". Fortune.
- Winslow R (24 January 2000). "The Birth of a Blockbuster: Lipitor's Route out of the Lab". The Wall Street Journal. Archived from the original on 7 April 2019. Retrieved 26 October 2011.
| Authority control databases: National |
|---|
